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reatment of enteric Fever
. Farrar
Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
With the global spread of enteric fever, the emergence of
almonella enterica serovar Paratyphi as a major pathogen (partic-
larly inAsia), the spread of drug resistance, and the global increase
n the incidence of non-Typhi salmonella, particularly in patients
oinfectedwith human immunodeﬁciency virus, there is nowmore
han ever a need for clinical research in enteric fever. There remains
iscussion among clinicians about the best treatment for enteric
ever, and large, pragmatic, well-designed, randomized controlled
rials are required to provide clear evidence. Vaccines and public
ealth measures will have the greatest long term impact on the
verall burden of disease; however, while we wait for these mea-
ures, prompt diagnosis and early treatmentwith the best available
nd affordable drug will help patients, reduce transmission within
he community, and potentially help to contain the spread of drug
esistance. A systematic approach and consensus on the design of
linical trials will improve the quality of these studies and facil-
tate the subsequent meta-analysis of the available data. Better
ntegration of clinical medicine with epidemiology, public health,
accine development, and modern laboratory science will help to
ield tangible beneﬁts for the vast number of people who have this
isease.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.078
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yphoid vaccine landscape
. Pollard
Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom
Some 27 million cases of enteric fever and over 200,000 deaths,
aused by Salmonella entericaserovar Typhi or Paratyphi, are esti-
ated to occur every year, with the highest number of cases
ecognised in South and Southeast Asia. The true burden of disease
s difﬁcult to estimate as a result of the poor sensitivity of blood cul-
ure and low sensitivity/speciﬁcity of serological tests. Paratyphoid
ccounts for up to 20-50% of disease in some geographic regions
nd is responsible for half of enteric fever in returning travellers
n the UK and US. The current licensed vaccines for typhoid (Vi
olysaccharide and live oral Ty21a vaccine) have some limitations
nd have not been widely deployed but there are no vaccines cur-
ently available for paratyphoid. For typhoid several Vi conjugate
accines are in development as well as a live oral attenuated sin-
le dose vaccine. For paratyphoid there are O-antigen conjugatenfectious Diseases 16S (2012) e2–e157
vaccines in early development and a live oral attenuated vaccine
providing the potential for comprehensive control of enteric fever.
While there is good evidence that provision of cleanwater and ade-
quate sanitation through economic development will eventually
eliminate enteric fever, the burden of infection will not be rapidly
reduced in themedium termwithout access to effective immunisa-
tion. There has been a lack of global advocacy to drive development
and implementation of typhoid vaccines until recently but there is
now growing momentum towards global prevention supported by
the Coalition Against Typhoid.
http://dx.doi.org/10.1016/j.ijid.2012.05.079
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Carriage of S. pneumoniae and related respiratory pathogens
after PCV-7 implementation
E. Sanders
Prof. in Pediatric Immunology and ID, Utrecht, Netherlands
The human nasopharynx is considered the niche from where
respiratory infections originate. Several common residents of
the nasopharyngeal microbiota, including Streptococcus pneumo-
niae,Haemophilus inﬂuenzae,Moraxella catarrhalis andStaphylococ-
cus aureus,are major contributors to respiratory and invasive
disease in childhood, especially in the youngest with their still
immature immune system. Colonisation of the upper respiratory
tract appears tobeadynamicprocess of acquisitionandelimination
of various microbial species, interacting with the host, its maturing
immune system and each other.
In the Netherlands, we performed a longitudinal randomized
controlled trial in 1003 infants investigating the effects of a 2- and
2+1-dose schedule with 7-valent pneumococcal conjugate vaccine
(PCV7) on pneumococcal presence and the potential changes in
carriage of H. inﬂuenzae, M. catarrhalis and S. aureus in children
and parents. We found a 60% reduction of PCV7-serotype pneu-
mococci and a concomitant increase of non-vaccine serotypes (in
particular serotype 19A) at age 24 months. We also found a dou-
bled prevalence of S. aureus at age 12 months, which declined in
the second year of life and no longer persisted at 24 months of age.
No signiﬁcant shifts in H. inﬂuenzae or M. catarrhalis carriage were
found.
Next, in two cross-sectional follow-up surveillance studies in
11- and 24-month-old children and parents performed 3 and
4.5 years after introduction of 3+1-dose PCV7-schedule in the
Dutch NIP, the overall pneumococcal carriage prevalence had
remained stable with PCV7-serotype pneumococci virtually absent
but substitutedbynon-PCV7serotypes.Again, a signiﬁcantlyhigher
prevalence of S. aureus was found in 11-month-old but not in 24-
month-old children. Furthermore, a higher carriage prevalence of
H. inﬂuenzae in children and parents was observed but no changes
in M. catarrhalis prevalence.
Our studies show that vaccine-induced shifts in pneumococ-
cal colonization may inﬂuence nasopharyngeal dynamics and the
presence of other respiratory pathogens, particularly S. aureus. This
may have implications for respiratory and invasive disease and
antibiotic treatment. Therefore, monitoring is mandatory.
